Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.76 |
| ▸ | S1PR3 | Q99500 | 18/20 | 0.72 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.63 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.63 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13576869 | 0.96 | S1PR1 (0.77) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497928 | 0.86 | S1PR1 (0.81) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497854 | 0.86 | S1PR1 (0.81) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL4330895 | 0.85 | S1PR1 (0.72) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497955 | 0.85 | S1PR1 (0.74) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497967 | 0.85 | S1PR1 (0.76) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497912 | 0.85 | S1PR1 (0.68) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497903 | 0.85 | S1PR1 (0.65) | S1PR1S1PR3 | |
| SCHEMBL1497796 | 0.85 | S1PR1 (0.65) | S1PR1S1PR3 | |
| SCHEMBL6036013 | 0.85 | S1PR1 (0.53) | S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622860-B1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORs | NOVARTIS AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| EP-1622860-B1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORs | NOVARTIS AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-7625950-B2 | Mono phosphoric acid mono-{2-amino-2-hydroxymethyl-4-[4-(3-phenoxy-propoxy)-phenyl]-butyl} ester; treatment, prevention of diseases or disorders mediated by lymphocytes interactions in transplantation; anticarcinogenic agent, antiinflammatory agent, antiproliferative agent, antidiabetic agent | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-7625950-B2 | Mono phosphoric acid mono-{2-amino-2-hydroxymethyl-4-[4-(3-phenoxy-propoxy)-phenyl]-butyl} ester; treatment, prevention of diseases or disorders mediated by lymphocytes interactions in transplantation; anticarcinogenic agent, antiinflammatory agent, antiproliferative agent, antidiabetic agent | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-7625950-B2 | Mono phosphoric acid mono-{2-amino-2-hydroxymethyl-4-[4-(3-phenoxy-propoxy)-phenyl]-butyl} ester; treatment, prevention of diseases or disorders mediated by lymphocytes interactions in transplantation; anticarcinogenic agent, antiinflammatory agent, antiproliferative agent, antidiabetic agent | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-20060211658-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| EP-1622860-A1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096752-A1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211658-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.